An early phase study testing an anti-PDL1 agent in combination with standard chemotherapy in the treatment of advanced non-small cell lung cancer has provided promising early results, prompting multiple phase III studies in lung cancer.

Source: Experimental immunotherapy shows high response rate in advanced lung cancer


David Cottle

UBB Owner & Administrator